MYLIP Genotype

Your cholesterol numbers tell you what is in your blood right now. They do not tell you why. A small set of inherited variants in the MYLIP gene (also called IDOL) help tune how aggressively your liver pulls cholesterol out of your bloodstream, and they may be quietly shaping your lipid panel before any food or medication enters the picture.

This test reports your MYLIP genotype, a fixed result you carry for life. It will not change after this draw, but knowing it can sharpen how you read your lipid trends, how seriously you take family history, and how early you act on the modifiable parts of your cardiovascular risk.

What MYLIP Does

MYLIP (myosin regulatory light chain interacting protein) is sometimes called IDOL, short for inducible degrader of the LDL receptor. The job of its protein product is to tag LDL receptors so the cell breaks them down inside lysosomes (the cell's recycling compartments). LDL receptors sit on liver cells and grab cholesterol-carrying particles out of the blood. The more LDL receptors you keep on the cell surface, the more cholesterol your liver pulls in. The more MYLIP activity, the fewer receptors, and the more cholesterol stays in circulation.

Two MYLIP variants have been studied most in humans. One, called N342S (rs9370867), changes a single amino acid in the protein. The other, rs3757354, sits in a non-coding region but tracks with lipid differences in some populations. Both have been linked to cholesterol traits, though the size and direction of the link depends on who is being studied.

Why This Genotype Matters

In a Mexican cohort with dyslipidemia, carriers of the Asn (N) allele at N342S had higher total cholesterol, and cellular experiments showed that this version of the protein more aggressively destroyed LDL receptors and cut LDL uptake. A separate study in Han Chinese individuals from Xinjiang found the same rs9370867 variant acted as an independent risk factor for hyperlipidemia.

For rs3757354, a study of Chinese Bai Ku Yao and Han participants found that G-allele carriers in the Bai Ku Yao group had higher HDL cholesterol, while in the Han group the GA genotype was tied to lower total cholesterol, HDL-C, and ApoAI (apolipoprotein A1, the main protein of HDL particles), and the effect appeared mainly in women. The same variant has also been linked to a higher risk of early-onset preeclampsia in Chinese pregnant women in a single candidate-gene study, with TT genotype carriers showing roughly three times the odds compared to other genotypes. This preeclampsia finding has not yet been replicated in larger genome-wide studies, so it should be read as preliminary.

Why the Evidence Looks Mixed

Not every study has found a signal. A Brazilian analysis of 2,720 people found no association between the N342S variant and lipid profile, blood pressure, or coronary angiography findings. An Italian study in a free-living population, and a follow-up study of 1,384 Italians tracking atherosclerosis progression, both came back negative for the same variant.

This is not a contradiction so much as a reminder of how MYLIP works. The variant frequencies differ sharply by ancestry, and its effect appears to interact with sex and with the rest of your cholesterol-handling machinery. A MYLIP variant that nudges cholesterol upward in one population may be drowned out by other genetic and lifestyle factors elsewhere. Think of it less as a switch and more as a thumb on the scale, the weight of which depends on what else is on the scale.

Connection to LDL Receptor Biology

MYLIP belongs to the same regulatory circuit as the LDL receptor itself and PCSK9, both well-established targets of cholesterol-lowering drugs. A study identified a loss-of-function MYLIP variant (p.Arg266X) in a Dutch cohort of people with unusually low circulating LDL cholesterol, supporting the idea that less MYLIP activity means more LDL receptors and lower blood cholesterol.

That same biology is why MYLIP variants associated with higher protein activity, like the N allele at N342S in some populations, can drift your cholesterol upward across decades of life even when your diet and exercise look reasonable on paper.

What a One-Time Result Means for You

This is a genetic test. Your genotype does not change, so you do not need to repeat it. The value comes from how you use the result to drive everything else you measure. If you carry a higher-risk variant, the case for tracking your lipid panel more frequently, watching ApoB (apolipoprotein B, a count of all artery-clogging particles) instead of just LDL-C, and acting on borderline numbers gets stronger.

For dynamic lipid markers like LDL-C, ApoB, and Lp(a) (lipoprotein little-a, an inherited particle that raises heart disease risk), get a baseline now, retest in 3 to 6 months if you change diet or start a medication, and at least annually after that. Your MYLIP result sets the backdrop. Your lipid panels show you what the body is actually doing against that backdrop.

When Results Can Be Misleading

Several things specific to genetic testing can distort how you read this result:

• Variant panel coverage: this test reports the specific MYLIP variants the assay is designed to detect. A result that does not flag a known risk variant does not rule out other rare changes in the same gene.
• Ancestry-specific frequencies: the N342S and rs3757354 variants show different allele frequencies and different clinical effects across populations. A result that carries one meaning in a Mexican or Han Chinese cohort may have a smaller or larger real-world effect for you depending on your background.
• Variants of uncertain significance: if the assay reports an unexpected MYLIP change with unclear meaning, treat that as information to discuss with a clinician, not as a verdict.
• Direct-to-consumer vs clinical genotyping: if you have seen MYLIP-related results from a consumer ancestry report, the genotype call may be correct but the interpretation oversimplified. A clinical-grade assay paired with a current lipid panel is a better basis for decisions.

Decision Pathway for an Out-of-Pattern Result

If you carry a MYLIP variant linked to higher cholesterol, the next move is not to retest the gene. It is to order or update the phenotype tests that actually tell you whether your lipids and arteries are responding. A reasonable workup includes ApoB and Lp(a) alongside a standard lipid panel, hs-CRP (high-sensitivity C-reactive protein, a measure of low-grade inflammation), and a fasting metabolic profile.

If those phenotype markers are also elevated, the combination is a stronger signal to lower the threshold for treatment, consider seeing a lipidologist or preventive cardiologist, and bring up testing in first-degree relatives. If they look clean despite the genotype, your other genes and lifestyle are likely compensating, and the result becomes a reason to keep tracking rather than to start treatment. Share the result with biological siblings, children, and parents, because they may carry the same variant and benefit from earlier lipid screening themselves.